通过应用具有更长半衰期的正电子放射性核素来描绘生物学行为。
Mapping biological behaviors by application of longer-lived positron emitting radionuclides.
机构信息
Radioimmune & Inorganic Chemistry Section, ROB, NCI, NIH, Bethesda, MD 20892-1002, USA.
出版信息
Adv Drug Deliv Rev. 2013 Jul;65(8):1098-111. doi: 10.1016/j.addr.2012.10.012. Epub 2012 Nov 2.
With the technological development of positron emission tomography (PET) and the advent of novel antibody-directed drug delivery systems, longer-lived positron-emitting radionuclides are moving to the forefront to take important roles in tracking the distribution of biotherapeutics such as antibodies, and for monitoring biological processes and responses. Longer half-life radionuclides possess advantages of convenient on-site preparation procedures for both clinical and non-clinical applications. The suitability of the long half-life radionuclides for imaging intact monoclonal antibodies (mAbs) and their respective fragments, which have inherently long biological half-lives, has attracted increased interest in recent years. In this review, we provide a survey of the recent literature as it applies to the development of nine-selected longer-lived positron emitters with half-lives of 9-140h (e.g., (124)I, (64)Cu, (86)Y and (89)Zr), and describe the biological behaviors of radionuclide-labeled mAbs with respect to distribution and targeting characteristics, potential toxicities, biological applications, and clinical translation potentials.
随着正电子发射断层扫描（PET）技术的发展和新型抗体导向药物输送系统的出现，寿命更长的正电子发射放射性核素将发挥重要作用，用于跟踪抗体等生物疗法的分布，并监测生物过程和反应。半衰期更长的放射性核素具有便于临床和非临床应用的现场制备程序的优势。近年来，长半衰期放射性核素适用于成像完整的单克隆抗体（mAbs）及其各自的片段，这些片段具有固有的长生物学半衰期，这引起了人们越来越多的兴趣。在这篇综述中，我们调查了最近的文献，这些文献涉及开发半衰期为 9-140 小时的九种选定的长寿命正电子发射体（例如，（124）I、（64）Cu、（86）Y 和（89）Zr），并描述了放射性核素标记的 mAbs 的生物学行为，包括分布和靶向特征、潜在毒性、生物应用和临床转化潜力。
Zotero 插件